Search results
Results from the WOW.Com Content Network
Metformin is the main drug used for treatment, as it is normally used for patients with hyperglycemia. [15] Metformin reduces appetite and improves symptoms of hepatic steatosis and polycystic ovary syndrome. [4] Leptin can also be used to reverse insulin resistance and hepatic steatosis, to cause reduced food intake, and decrease blood glucose ...
Metformin was first described in scientific literature in 1922 by Emil Werner and James Bell. [29] French physician Jean Sterne began the study in humans in the 1950s. [29] It was introduced as a medication in France in 1957. [16] [30] It is on the World Health Organization's List of Essential Medicines. [31] It is available as a generic ...
Endocrinology. Lipodystrophy syndromes are a group of genetic or acquired disorders in which the body is unable to produce and maintain healthy fat tissue. [1][2] The medical condition is characterized by abnormal or degenerative conditions of the body's adipose tissue. A more specific term, lipoatrophy (from Greek lipo 'fat' and dystrophy ...
Patients with diabetes mellitus are more likely to experience certain infections, such as COVID-19, with prevalence rates ranging from 5.3 to 35.5%. [ 97 ] [ 98 ] Maintaining adequate glycemic control is the primary goal of diabetes management since it is critical to managing diabetes and preventing or postponing such complications.
However, another drug designed to assist with type 2 diabetes treatment, metformin, had a 13-year head start, receiving FDA approval in 2004. Though the two drugs can help people with the same ...
Diabetes medication. Drugs used in diabetes treat diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic ...
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...
Metformin is a member of the biguanide class, improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.